Summary: In adults with type 2 diabetes, adding a ketogenic diet to dulaglutide for 6 months improved glucose and lipid metabolism, insulin resistance, sleep quality, and quality of life more than dulaglutide alone, with no significant side effects reported.
PICO Summary
| Element | Detail |
|---|---|
| Population | 104 adults with type 2 diabetes in a randomised study. |
| Intervention | Dulaglutide plus a ketogenic diet for 6 months. |
| Comparison | Dulaglutide alone, without dietary modification. |
| Outcome | Combination lowered blood glucose and lipids (P<0.05), reduced insulin resistance and raised insulin sensitivity, and improved PSQI sleep and quality-of-life scores at 6 months versus control. No significant adverse effects reported. |
Expert Commentary
The pairing makes mechanistic sense, so I am not surprised it works on paper: a ketogenic diet strips out the exogenous glucose load while the GLP-1 agonist handles satiety and endogenous glucose, and the two ought to be complementary. My verdict is cautiously favourable but distinctly hedged, because the things that worry me about ketogenic diets are exactly the things this study does not report. It does not describe the degree of ketosis, the dietary composition, or how adherence was measured, and at six months I learn nothing about whether anyone can sustain this or what happens to LDL cholesterol and renal function over the longer term. There is also a practical safety point I cannot ignore: combining carbohydrate restriction with glucose-lowering therapy raises real hypoglycaemia and, with SGLT2 inhibitors, ketoacidosis concerns that demand dose adjustment and monitoring. Can I use this with my patients? Selectively, yes, for a motivated patient on a GLP-1 agonist who needs more and has dietitian support, but never as a blanket recommendation. I would want longer data on adherence and lipid safety before I push ketosis hard in this combination.
References
Gao R, Yan L, Du X, et al. Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus. Pak J Pharm Sci. 2025;38(6):2286–2291. doi:10.36721/PJPS.2025.38.6.REG.13419.1